Researchers at the University of Michigan have developed a compact blood-testing device designed to spot signs of sepsis, a life-threatening condition caused by the body’s extreme response to infection. The system, called the Smart Pipette, is built to analyze blood serum at the point of care, meaning testing can happen near the patient instead of in a central lab. That matters because sepsis can worsen quickly, and every hour of delay can make treatment less effective. The device measures four immune-related biomarkers, including procalcitonin and the signaling proteins IL-1b, IL-6, and IL-10, which can help reveal how severe a patient’s illness may be. To do that, it combines engineered gold nanoparticle sensor arrays with ultrathin photoconductive nanosheet channels inside a small disposable module. Results are delivered in about 30 minutes and can be sent to a smartphone for analysis. Machine learning software then helps interpret the pattern of biomarkers, offering clues about disease severity and possible treatment decisions. In short, the project aims to turn a slow, lab-dependent process into a faster bedside tool that could help clinicians act sooner.
A bedside test for a fast-moving emergency
Sepsis is difficult because it can look different from one patient to the next. Fever, low blood pressure, confusion, and rapid breathing may all appear, but none of those signs alone can confirm what is happening inside the body.
Doctors often rely on blood cultures to identify infection, but cultures can take many hours or even days. That waiting period can be dangerous when a patient needs treatment quickly, which is why faster biological readouts are so valuable.
How the Smart Pipette works
The Smart Pipette is a microchip-based diagnostic system, meaning it uses miniature electronic and sensing components to process a small sample of blood serum. Serum is the clear liquid left after blood cells and clotting proteins are removed, and it contains many molecules that can act as health indicators.
Inside the device are gold nanoparticle biosensor arrays. Gold nanoparticles are tiny bits of gold engineered at the scale of billionths of a meter, and they are useful because their surfaces can be tailored to latch onto specific biomarker molecules with high sensitivity.
The system also uses photoconductive nanosheet channels, ultrathin materials whose electrical behavior changes when they detect biological interactions. By pairing these nanosheets with the gold sensor arrays, the device can translate the presence of key biomarkers into a measurable electronic signal.
What the device measures
The disposable test is designed to detect four cytokine-related sepsis markers: procalcitonin, IL-1b, IL-6, and IL-10. Cytokines are signaling proteins that immune cells use to communicate, and abnormal levels can indicate that the body is mounting a harmful inflammatory response.
Each marker adds a different piece to the clinical picture. Procalcitonin is often associated with bacterial infection, while interleukins such as IL-1b, IL-6, and IL-10 can reflect the intensity and balance of inflammation, giving a more nuanced view than a single test alone.
From sensor to smartphone
One of the notable features of the platform is that data can be transmitted directly to a smartphone. This turns the device into more than a sensor: it becomes a connected decision-support tool that can fit into modern clinical workflows.
Once the readings are collected, machine learning algorithms analyze the biomarker pattern. Machine learning refers to software trained to recognize meaningful relationships in data, and in this case it is used to help estimate disease severity and suggest how the results might inform treatment choices.
Why speed changes the equation
The major promise of the system is timing. Delivering results in roughly 30 minutes could let clinicians assess sepsis risk long before traditional blood culture data arrives.
That speed does not necessarily replace every conventional test, but it could help guide early action when the window for effective intervention is narrow. In suspected sepsis, earlier decisions about antibiotics, monitoring, or escalation of care can have an outsized impact on outcomes.
Why This Matters
Point-of-care diagnostics like this one aim to move critical testing closer to the patient, where it can influence decisions in real time. For emergency departments, intensive care units, ambulances, and resource-limited settings, a disposable system that combines rapid sensing with smartphone-based analysis could reduce delays and expand access to advanced testing.
There is also a broader technology story here. By combining nanomaterials, microchip engineering, and software-based interpretation, the Smart Pipette reflects a larger shift in medicine toward compact platforms that do more than detect a molecule—they help translate measurements into clinically useful insight.
What comes next
Before systems like this become routine, they typically need further validation in larger patient groups and real clinical environments. Researchers and partners will need to show that the device is reliable, easy to use, and genuinely improves decision-making compared with current practice. But the concept is compelling: a small disposable chip that reads the body’s inflammatory signals, sends the data to a phone, and helps clinicians respond faster when minutes matter. If that promise holds up, point-of-care sepsis testing could become a powerful example of how biochips bring sophisticated diagnostics out of the lab and to the bedside.